Adverse events290

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

101 to 120 of 290

Type	Event	Organ system	Group	Affected	At risk
other	Myalgia	Musculoskeletal and connective tissue disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	4	30
other	Myalgia	Musculoskeletal and connective tissue disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	8	30
other	Myalgia	Musculoskeletal and connective tissue disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	10	30
other	Myalgia	Musculoskeletal and connective tissue disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	362	1,162
other	Myalgia	Musculoskeletal and connective tissue disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	306	1,161
other	Headache	Nervous system disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	10	30
other	Headache	Nervous system disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	14	30
other	Headache	Nervous system disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	13	30
other	Headache	Nervous system disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	444	1,162
other	Headache	Nervous system disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	432	1,161
other	Nasal congestion	Respiratory, thoracic and mediastinal disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	0	30
other	Nasal congestion	Respiratory, thoracic and mediastinal disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	0	30
other	Nasal congestion	Respiratory, thoracic and mediastinal disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	2	30
other	Nasal congestion	Respiratory, thoracic and mediastinal disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	4	1,162
other	Nasal congestion	Respiratory, thoracic and mediastinal disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	3	1,161
other	Dermatitis contact	Skin and subcutaneous tissue disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	2	30
other	Dermatitis contact	Skin and subcutaneous tissue disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	0	30
other	Dermatitis contact	Skin and subcutaneous tissue disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	1	30
other	Dermatitis contact	Skin and subcutaneous tissue disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	2	1,162
other	Dermatitis contact	Skin and subcutaneous tissue disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	3	1,161

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03110770/events?page=6

API reference For AI assistants